Transcription of DRUG NAME: Crizotinib - BC Cancer
{{id}} {{{paragraph}}}
Example: stock market
DRUG NAME: Crizotinib - BC Cancer
Crizotinib BC Cancer Agency Cancer drug Manual Page 1 of 6 Crizotinib Developed: 1 April 2014 Revised: 1 September 2014 drug NAME: Crizotinib SYNONYM(S): COMMON TRADE NAME(S): XALKORI CLASSIFICATION: tyrosine kinase inhibitor Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Crizotinib is an oral selective small molecule tyrosine kinase inhibitor which targets anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-Met), and ROS1 tyrosine kinases. Crizotinib demonstrates potent growth inhibitory activity and induces apoptosis in tumour cell lines exhibiting ALK fusion events or ALK or MET gene amplification. Antitumour efficacy is dose-dependent. A validated ALK assay should be used to confirm ALK-positive ,2 PHARMACOKINETICS: Oral Absorption aqueous solubility is pH dependent; median time to peak concentration is 4 h; high fat meal reduces AUC and Cmax by ~14% Distribution extensive distribution to tissues cross blood brain barrier?
Crizotinib BC Cancer Agency Cancer Drug Manual© Page 2 of 6 Crizotinib Developed: 1 April 2014 Revised: 1 September 2014. Caution: • vision disorders. have been reported; ability to drive or operate machinery may be compromised.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: